-
Alex Kentsis
- Jul 29, 2021
Helen Mueller
Helen received her BA in Biology from Columbia University. She then received her PhD from the Massachusetts Institute of Technology, where she studied the mechanisms and consequences of resistance to epigenetic targeted therapy in lung cancer. Her current research interests include elucidating and targeting transposase-activated signaling pathways in childhood cancers.
